The Experts below are selected from a list of 12 Experts worldwide ranked by ideXlab platform

Bjarne Østerud - One of the best experts on this subject based on the ideXlab platform.

  • Effects of two triphasic oral contraceptives containing Ethinylestradiol Plus Levonorgestrel or gestodene on blood coagulation and fibrinolysis.
    Acta Obstetricia et Gynecologica Scandinavica, 2011
    Co-Authors: Ivar H. Omsjø, Pal Oian, Jan Martin Maltau, Bjarne Østerud
    Abstract:

    The hemostatic effects of a new triphasic oral contraceptive combination containing Ethinylestradiol and the new progestogen gestodene were compared with those of a triphasic combination of Ethinylestradiol and Levonorgestrel. A total of 19 women who did not use any kind of hormonal contraception 3 months prior to the study were recorded. The following parameters were measured: whole blood clotting time (WBCT), whole blood clot lysis time, fibrinogen, antithrombin III, factors V, VII and VIII. Blood samples were taken before treatment and in cycles 1, 3 and 6. A significant shortening of WBCT was observed in cycle 3 and 6 in both groups and also in cycle 1 in the gestodene group. This may indicate an increased sensitivity for activation of platelets, since the assay appears to be quite sensitive to this process. In the other parameters tested there were no significant changes except for a slight increase in plasma fibrinogen in cycle 1 in the gestodene group.

Ivar H. Omsjø - One of the best experts on this subject based on the ideXlab platform.

  • Effects of two triphasic oral contraceptives containing Ethinylestradiol Plus Levonorgestrel or gestodene on blood coagulation and fibrinolysis.
    Acta Obstetricia et Gynecologica Scandinavica, 2011
    Co-Authors: Ivar H. Omsjø, Pal Oian, Jan Martin Maltau, Bjarne Østerud
    Abstract:

    The hemostatic effects of a new triphasic oral contraceptive combination containing Ethinylestradiol and the new progestogen gestodene were compared with those of a triphasic combination of Ethinylestradiol and Levonorgestrel. A total of 19 women who did not use any kind of hormonal contraception 3 months prior to the study were recorded. The following parameters were measured: whole blood clotting time (WBCT), whole blood clot lysis time, fibrinogen, antithrombin III, factors V, VII and VIII. Blood samples were taken before treatment and in cycles 1, 3 and 6. A significant shortening of WBCT was observed in cycle 3 and 6 in both groups and also in cycle 1 in the gestodene group. This may indicate an increased sensitivity for activation of platelets, since the assay appears to be quite sensitive to this process. In the other parameters tested there were no significant changes except for a slight increase in plasma fibrinogen in cycle 1 in the gestodene group.

Pal Oian - One of the best experts on this subject based on the ideXlab platform.

  • Effects of two triphasic oral contraceptives containing Ethinylestradiol Plus Levonorgestrel or gestodene on blood coagulation and fibrinolysis.
    Acta Obstetricia et Gynecologica Scandinavica, 2011
    Co-Authors: Ivar H. Omsjø, Pal Oian, Jan Martin Maltau, Bjarne Østerud
    Abstract:

    The hemostatic effects of a new triphasic oral contraceptive combination containing Ethinylestradiol and the new progestogen gestodene were compared with those of a triphasic combination of Ethinylestradiol and Levonorgestrel. A total of 19 women who did not use any kind of hormonal contraception 3 months prior to the study were recorded. The following parameters were measured: whole blood clotting time (WBCT), whole blood clot lysis time, fibrinogen, antithrombin III, factors V, VII and VIII. Blood samples were taken before treatment and in cycles 1, 3 and 6. A significant shortening of WBCT was observed in cycle 3 and 6 in both groups and also in cycle 1 in the gestodene group. This may indicate an increased sensitivity for activation of platelets, since the assay appears to be quite sensitive to this process. In the other parameters tested there were no significant changes except for a slight increase in plasma fibrinogen in cycle 1 in the gestodene group.

Jan Martin Maltau - One of the best experts on this subject based on the ideXlab platform.

  • Effects of two triphasic oral contraceptives containing Ethinylestradiol Plus Levonorgestrel or gestodene on blood coagulation and fibrinolysis.
    Acta Obstetricia et Gynecologica Scandinavica, 2011
    Co-Authors: Ivar H. Omsjø, Pal Oian, Jan Martin Maltau, Bjarne Østerud
    Abstract:

    The hemostatic effects of a new triphasic oral contraceptive combination containing Ethinylestradiol and the new progestogen gestodene were compared with those of a triphasic combination of Ethinylestradiol and Levonorgestrel. A total of 19 women who did not use any kind of hormonal contraception 3 months prior to the study were recorded. The following parameters were measured: whole blood clotting time (WBCT), whole blood clot lysis time, fibrinogen, antithrombin III, factors V, VII and VIII. Blood samples were taken before treatment and in cycles 1, 3 and 6. A significant shortening of WBCT was observed in cycle 3 and 6 in both groups and also in cycle 1 in the gestodene group. This may indicate an increased sensitivity for activation of platelets, since the assay appears to be quite sensitive to this process. In the other parameters tested there were no significant changes except for a slight increase in plasma fibrinogen in cycle 1 in the gestodene group.

Hasan Cetin Ekerbicer - One of the best experts on this subject based on the ideXlab platform.

  • Serum lipid and lipoprotein changes induced by preparations containing low-dose Ethinylestradiol Plus Levonorgestrel
    The Australian & New Zealand journal of obstetrics & gynaecology, 2003
    Co-Authors: Gürkan Kıran, Hakan Kiran, Hasan Cetin Ekerbicer
    Abstract:

    The purpose of the present study was to evaluate the effects on lipid metabolism of a new low-dose monophasic combination oral contraceptive with 100 µg Levonorgestrel and 20 µg Ethinylestradiol. Sixty healthy women aged 18-45 years were administered the medication during three cycles. The study participants were screened for lipid changes. The differences in cholesterol and triglyceride levels were not statistically significant but high-density lipoprotein levels were significantly lower and low-density lipoprotein levels were significantly higher than the baseline. Women at risk of cardiovascular disease should be carefully monitored even when using low-dose preparations. (authors)